Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 W 4th Avenue, Vancouver, Canada

bonecrack_benny May. 15 at 8:01 PM

$ABCL stay strong the a few weeks my brothers and sisters. Weak ones leaving and strong ones accumulating.

0 · Reply

tradersunion353 May. 15 at 7:05 PM

$ABCL Seriously what are this bullish clowns celebrating for? I mean scam dropped 30% on phase 1 data.. what is bullish in this until or unless you are paid to pump this I am investor in ABCL too, if you are real investor anyone would be worried about the stock pos performance for over 5 years, I understand you are paid to pump .. this is just insane

0 · Reply

tradersunion353 May. 15 at 5:49 PM

$ABCL Fake longs how is your paper trading those adding and loading happening?

3 · Reply

TradeWinner May. 15 at 5:05 PM

$ABCL ho hum. Whole market is red. Q2 is half done. Q3 results will be here soon and excitement will Build as they get closer.

1 · Reply

Stocktradesmoon May. 15 at 4:55 PM

$ABCL $ABCL The whole market is down, but anything under $4 could be a generational opportunity. If you tune out the daily noise and come back a year later, you would do great. I will load more under $4 if we EVER see that number.

0 · Reply

TornadoChasers May. 15 at 4:48 PM

$ABCL $FBIO $SNDX $TGTX CZ

2 · Reply

tradersunion353 May. 15 at 4:33 PM

$ABCL clowns aka paid pumpers are getting excited with adding and loading their paper trades 😂😂😂

0 · Reply

hichemben May. 15 at 4:24 PM

$ABCL double-edged sword > Sell the news + XBI is down 3 days in a raw! Its the stock market, and it will go up over time! Short term pain for long term gain, we will consolidate, and move up🙏🏼💎🚀

0 · Reply

Rastafari May. 15 at 4:18 PM

$ABCL get ready for whiplash! The rebound will be wicked! Today is all about flushing out the scardy cats!

0 · Reply

DeMampCamp May. 15 at 4:09 PM

$ABCL Headed for the 50ma!

0 · Reply

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T10:58:11.000Z - 3 days ago

AbCellera price target raised to $8 from $7 at Stifel

2026-05-11T21:58:40.000Z - 3 days ago

AbCellera Biologics options imply 9.7% move in share price post-earnings

May 11, 2026, 5:00 PM EDT - 3 days ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 4:05 PM EDT - 4 days ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 7, 2026, 4:05 PM EDT - 8 days ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

2026-05-05T10:36:31.000Z - 10 days ago

AbCellera initiated with an Overweight at Cantor Fitzgerald

Apr 21, 2026, 1:30 PM EDT - 24 days ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 20, 2026, 9:00 AM EDT - 25 days ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

2026-04-09T20:10:26.000Z - 5 weeks ago

AbCellera initiated with a Buy at JonesResearch

Apr 1, 2026, 4:05 PM EDT - 6 weeks ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Mar 17, 2026, 4:30 PM EDT - 2 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 4, 2026, 9:50 AM EST - 2 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 5:00 PM EST - 2 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

2026-02-24T21:15:21.000Z - 2 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year

Feb 24, 2026, 4:05 PM EST - 2 months ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 3 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 4 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 14, 2026, 6:45 PM EST - 4 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-12T14:36:23.000Z - 4 months ago

AbCellera doses first patients in Phase 2 portion of ABCL635 trial

Jan 12, 2026, 9:00 AM EST - 4 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

2025-12-18T14:20:19.000Z - 5 months ago

AbCellera to receive $36M upfront in patent litigation settlement with Bruker

BRKR

Dec 18, 2025, 9:00 AM EST - 5 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 5 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 3, 2025, 8:00 AM EST - 5 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 6 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 6 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

2025-11-07T11:16:20.000Z - 6 months ago

AbCellera downgraded to Market Perform from Outperform at Leerink

Nov 6, 2025, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:05 PM EST - 6 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 7 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Sep 29, 2025, 4:05 PM EDT - 8 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

2025-09-10T13:20:54.000Z - 8 months ago

AbCellera appoints Sarah Noonberg as Chief Medical Officer

MGX

Sep 10, 2025, 9:07 AM EDT - 8 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 5, 2025, 9:30 AM EDT - 9 months ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

2025-08-27T13:20:26.000Z - 9 months ago

AbCellera doses first participants in Phase 1 trial of ABCL575

Aug 27, 2025, 9:00 AM EDT - 9 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 9 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

2025-08-08T13:26:29.000Z - 10 months ago

AbCellera price target raised to $7 from $5 at BMO Capital

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 10 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Jul 7, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

2025-07-07T10:40:33.000Z - 11 months ago

AbCellera assumed with an Outperform at Leerink

2025-06-11T13:45:23.000Z - 1 year ago

Unusually active option classes on open June 11th

AFRM BILI FXE LAES PCG QUBT RGTI

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

2025-05-30T17:05:30.000Z - 1 year ago

AbCellera receives Health Canada authorization to initiate ABCL575 Phase 1 trial

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 17, 2024, 11:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 5, 2024, 3:00 PM EDT - 1 year ago

AbCellera Biologics Transcript: 2024 Wells Fargo Healthcare Conference

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 6, 2024, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

Jun 10, 2024, 3:20 PM EDT - 2 years ago

AbCellera Biologics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

May 28, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results

May 1, 2024, 9:00 AM EDT - 2 years ago

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

Apr 16, 2024, 10:00 AM EDT - 2 years ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference

Apr 8, 2024, 12:05 PM EDT - 2 years ago

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Apr 3, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024

Mar 20, 2024, 11:15 AM EDT - 2 years ago

AbCellera Biologics Transcript: KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 19, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024

Mar 11, 2024, 9:00 AM EDT - 2 years ago

AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

BIIB

Mar 5, 2024, 4:30 PM EST - 2 years ago

AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

bonecrack_benny May. 15 at 8:01 PM

$ABCL stay strong the a few weeks my brothers and sisters. Weak ones leaving and strong ones accumulating.

0 · Reply

tradersunion353 May. 15 at 7:05 PM

0 · Reply

tradersunion353 May. 15 at 5:49 PM

$ABCL Fake longs how is your paper trading those adding and loading happening?

3 · Reply

TradeWinner May. 15 at 5:05 PM

$ABCL ho hum. Whole market is red. Q2 is half done. Q3 results will be here soon and excitement will Build as they get closer.

1 · Reply

Stocktradesmoon May. 15 at 4:55 PM

0 · Reply

TornadoChasers May. 15 at 4:48 PM

$ABCL $FBIO $SNDX $TGTX CZ

2 · Reply

tradersunion353 May. 15 at 4:33 PM

$ABCL clowns aka paid pumpers are getting excited with adding and loading their paper trades 😂😂😂

0 · Reply

hichemben May. 15 at 4:24 PM

0 · Reply

Rastafari May. 15 at 4:18 PM

$ABCL get ready for whiplash! The rebound will be wicked! Today is all about flushing out the scardy cats!

0 · Reply

DeMampCamp May. 15 at 4:09 PM

$ABCL Headed for the 50ma!

0 · Reply

Ed_Ng May. 15 at 4:00 PM

$ABCL Canadian gov will tale loss soon

0 · Reply

Kaykay610 May. 15 at 3:55 PM

$ABCL https://www.instagram.com/reel/DUwY2yRiQk5/?igsh=MXB5N2MwM2JpM2p2bQ==

0 · Reply

DeMampCamp May. 15 at 3:53 PM

$ABCL It's very clear they want to break under $4 today, the real question is, are they going to keep it under $4 and pay the puts?

2 · Reply

tradersunion353 May. 15 at 3:50 PM

$ABCL overhyped SCAM

0 · Reply

Samb2344 May. 15 at 3:24 PM

$ABCL bought more today.

1 · Reply

Stocktradesmoon May. 15 at 3:20 PM

$ABCL Biggest regret in my investing journey has been trading in and out of winners. Conviction, Thesis and Patience goes a long way! People want 10x returns but don’t have the 10x patience!

0 · Reply

Stocktradesmoon May. 15 at 3:17 PM

$ABCL $ABCL my quant says we close green today

2 · Reply

Cello69 May. 15 at 3:13 PM

$ABCL $5.65 to $4 in 3 days HMMMMMMM..... OK

0 · Reply

Kaykay610 May. 15 at 3:09 PM

$ABCL bought more $4.X calls 2028 they are tooooo cheap!!

0 · Reply

tradersunion353 May. 15 at 3:09 PM

$ABCL Demamp clown with different narrative whenever this scam drops hard 👇 🤣🤣

0 · Reply

DeMampCamp May. 15 at 3:07 PM

$ABCL I honestly can’t relate to people who root for their own investments to fall. If you’re actively hoping the stock drops, why are you even invested in it? We’re all here to make money, literally the opposite is happening when you're wanting it lower, makes ZERO sense to me! I'd rather have to average UP instead of down 100 times out of 100 times!

2 · Reply

tradersunion353 May. 15 at 3:05 PM

$ABCL Clowns aka who is married to this scam. How is your adding and loading working Did that clown Demamp motivate you well to lose your money? 🤣

0 · Reply

Market Cap	1.46B
Revenue (ttm)	75.13M
Net Income (ttm)	-146.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-194.88%
Debt to Equity Ratio	0.00

Volume	7,618,897
Avg Vol	5,225,826
Day's Range	N/A - N/A
Shares Out	305.38M
Stochastic %K	3%
Beta	1.02
Analysts	Strong Sell
Price Target	$10.14